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Background
The proteasome inhibitor bortezomib was initially approved for the treatment of re-
lapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for 
vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxo-
rubicin, vincristine, and prednisone) could improve outcomes in patients with new-
ly diagnosed mantle-cell lymphoma.
Methods
In this phase 3 trial, we randomly assigned 487 adults with newly diagnosed mantle-
cell lymphoma who were ineligible or not considered for stem-cell transplantation 
to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 (with predni-
sone administered orally on days 1 to 5) or VR-CAP (R-CHOP regimen, but replacing 
vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface 
area on days 1, 4, 8, and 11). The primary end point was progression-free survival.
Results
After a median follow-up of 40 months, median progression-free survival (accord-
ing to independent radiologic review) was 14.4 months in the R-CHOP group versus 
24.7 months in the VR-CAP group (hazard ratio favoring the VR-CAP group, 0.63; 
P<0.001), a relative improvement of 59%. On the basis of investigator assessment, 
the median durations of progression-free survival were 16.1 months and 30.7 months, 
respectively (hazard ratio, 0.51; P<0.001), a relative improvement of 96%. Secondary 
end points were consistently improved in the VR-CAP group, including the com-
plete response rate (42% vs. 53%), the median duration of complete response 
(18.0 months vs. 42.1 months), the median treatment-free interval (20.5 months vs. 
40.6 months), and the 4-year overall survival rate (54% vs. 64%). Rates of neutro-
penia and thrombocytopenia were higher in the VR-CAP group.
Conclusions
VR-CAP was more effective than R-CHOP in patients with newly diagnosed mantle-
cell lymphoma but at the cost of increased hematologic toxicity. (Funded by Janssen 
Research and Development and Millennium Pharmaceuticals; LYM-3002 ClinicalTrials 
.gov number, NCT00722137.)
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Mantle-cell lymphoma is an incur-able, aggressive hematologic cancer with a poor prognosis (median survival, 
4 to 5 years).1,2 It comprises 5 to 6% of all non-
Hodgkin’s lymphomas, including approximately 
5000 cases per year in the United States.3 For 
previously untreated patients who are either in-
eligible or not considered for intensive chemo-
therapy and stem-cell transplantation, R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vin-
cristine, and prednisone) is a standard of care4-6 
and produces complete response rates of up to 
48%. However, progression-free survival is lim-
ited (median, 16.6 months).7
The proteasome inhibitor bortezomib was 
initially approved for the treatment of relapsed 
mantle-cell lymphoma in the United States8 and 
in 53 other countries on the basis of phase 2, 
single-agent data showing durable responses and 
favorable rates of progression-free survival and 
overall survival, with predictable toxic effects.9-11 
In this phase 3 trial, LYM-3002, we investigated 
whether substituting bortezomib for vincristine 
(because of concern over potential overlapping 
neurotoxicity if the two drugs were administered 
in the same regimen)12 in frontline R-CHOP could 
improve outcomes in patients with mantle-cell 
lymphoma. We assessed the efficacy and safety 
of R-CHOP versus combination therapy with 
bortezomib, rituximab, cyclophosphamide, doxo-
rubicin, and prednisone (VR-CAP) in patients 
with newly diagnosed disease in whom stem-cell 
transplantation was not an option.
Me thods
Study Patients
From May 2008 through December 2011, we en-
rolled patients at 128 sites in 28 countries across 
Europe, Asia, North America, and South America. 
Adults with newly diagnosed stage II, III, or IV 
mantle-cell lymphoma who were ineligible or not 
considered for stem-cell transplantation were eli-
gible. (Complete eligibility criteria are provided 
in the Supplementary Appendix, available with 
the full text of this article at NEJM.org.) The 
diagnosis was confirmed on central pathological 
review.
The trial was conducted according to the pro-
visions of the Declaration of Helsinki, Good 
Clinical Practice guidelines, and local regulatory 
requirements. The local ethics committee or in-
stitutional review board at each site approved the 
study protocol, which is available at NEJM.org. 
All patients provided written informed consent.
Study Oversight
The database lock for the primary analysis was 
January 10, 2014. The trial was designed by the 
academic authors in collaboration with employees 
of Janssen Research and Development, the sole 
legal sponsor of the study. Millennium Pharma-
ceuticals cofunded the study. Data were gathered 
by the investigators and Janssen employees, ana-
lyzed by the Janssen coauthors, and interpreted 
by the first and last authors, the academic co-
authors, and the Janssen coauthors. The first and 
last authors and the Janssen coauthors vouch for 
the integrity, accuracy, and completeness of the 
data analyses and for the fidelity of the study to 
the protocol. The initial draft was written by the 
first and last authors, the Janssen coauthors, and 
a medical writer employed by FireKite and paid 
by Janssen and Millennium Pharmaceuticals. All 
authors were involved in manuscript develop-
ment and approved the final draft. The decision 
to submit the manuscript for publication was 
made by the first and last authors and agreed by 
the coauthors.
Study Treatments
Patients were stratified according to their score 
on the International Prognostic Index (IPI), with 
risks categorized as low (a score of 0 or 1), low–
intermediate (a score of 2), high–intermediate (a 
score of 3), or high (a score of 4 or 5) (Table S1 in 
the Supplementary Appendix), and disease stage 
at diagnosis (stage II, III, or IV according to the 
staging system for non-Hodgkin’s lymphoma of 
the American Joint Committee on Cancer). Pa-
tients were randomly assigned in a 1:1 ratio to 
receive six 21-day cycles of R-CHOP or VR-CAP. 
Patients could receive up to eight cycles if a re-
sponse was first documented at cycle 6. R-CHOP 
comprised rituximab (at a dose of 375 mg per 
square meter of body-surface area), cyclophos-
phamide (750 mg per square meter), doxorubicin 
(50 mg per square meter), and vincristine (1.4 mg 
per square meter, with a maximum total dose of 
2 mg), all administered intravenously on day 1, 
plus oral prednisone (100 mg per square meter) 
administered on days 1 to 5. VR-CAP comprised 
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intravenous bortezomib (1.3 mg per square me-
ter) on days 1, 4, 8, and 11 of each cycle (admin-
istered first on day 1), followed by rituximab 
(administered second on day 1) and cyclophos-
phamide, doxorubicin, and prednisone, all as de-
scribed above.
All study drugs were provided from a central 
supply and paid for by the study budget. A 
permuted-block central randomization plan with 
a computer-generated randomization schedule 
(sponsor-generated) was used. Concomitant treat-
ments and prophylactic medications are sum-
marized in the Methods section in the Supple-
mentary Appendix. Dose adjustments for toxic 
effects were permitted with the use of estab-
lished dose-modification guidelines per the pre-
scribing information for each drug.
Study End Points and Assessments
The primary end point was progression-free sur-
vival. The primary analysis was based on a blind-
ed assessment of disease progression that was 
performed by an independent radiology review 
committee. Progression-free survival according 
to investigator assessment was used as supportive 
evidence. Prespecified secondary end points in-
cluded the overall response rate (complete re-
sponse or unconfirmed complete response and 
partial response), complete response rate (radio-
logic complete response or radiologic uncon-
firmed complete response, which both had to be 
verified by evidence of bone marrow clearance 
and normalization of the lactate dehydrogenase 
level), time to and duration of response, time to 
progression, time to next antilymphoma therapy, 
overall survival, and safety. All secondary end 
points are listed in the Methods section in the 
Supplementary Appendix.
Computed tomographic (CT) scans were per-
formed every two cycles during treatment and 
every 6 to 8 weeks during follow-up until disease 
progression, study discontinuation, initiation of 
alternative therapy, or death. All CT results were 
assessed in a blinded fashion by the independent 
review committee and by investigators, accord-
ing to the modified criteria of the International 
Workshop to Standardize Response Criteria for 
Non-Hodgkin’s Lymphoma (Table S2 in the Sup-
plementary Appendix).13 Adverse events were 
graded according to the National Cancer Insti-
tute Common Terminology Criteria for Adverse 
Events, version 3.0.14 A central immunohisto-
chemical analysis was performed to assess the 
expression of the prognostic marker Ki-6715-18 
with the use of paraffin-embedded, formalin-
fixed, or frozen tumor samples (see the Supple-
mentary Appendix for details). Ki-67–positive 
status was defined as an expression of more 
than 10% on an ordinal scale (the accepted cutoff 
for prognostic significance).15
Statistical Analysis
An independent data and safety monitoring com-
mittee oversaw the conduct of the study. It was 
estimated that 295 events of disease progression 
or death would provide a power of 80% (at a two-
sided alpha level of 0.05) to detect a 40% im-
provement in the median progression-free sur-
vival (from 18 to 25 months) with VR-CAP, as 
compared with R-CHOP. Assuming a data-accru-
al period of 24 months and 18 months of follow-
up, we determined that 486 patients (243 per study 
group) were required. Three preplanned interim 
analyses were conducted.
All primary and secondary efficacy analyses 
were performed in the intention-to-treat popula-
tion, except for response end points (which were 
analyzed in the response-evaluable population) 
and treatment-free interval (which was analyzed 
in the safety population). (Details regarding the 
analysis populations are provided in the Methods 
section in the Supplementary Appendix.)
We used Kaplan–Meier methods to estimate 
time-to-event distributions, with stratified log-
rank tests and Cox models used for between-
group comparisons of time-to-event end points. 
We conducted prespecified subgroup analyses of 
progression-free survival according to IPI risk 
score, sex, race, region, age, disease stage at diag-
nosis, performance status (according to Eastern 
Cooperative Oncology Group criteria), lactate de-
hydrogenase level, and white-cell count.
We also performed post hoc analyses of pro-
gression-free survival according to mantle-cell 
lymphoma–specific IPI (MIPI) risk category,19,20 
Ki-67 expression status (≤10% vs. >10%), and 
MIPI with biologic component (MIPIb)19,20 risk 
category in patients with baseline Ki-67 assess-
ment. We used a stratified Cochran–Mantel–
Haenszel chi-square test with IPI and disease 
stage as stratification factors to assess between-
group differences in response rates.
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R esult s
Patients
A total of 487 patients underwent randomization 
to receive either R-CHOP (244 patients) or VR-CAP 
(243 patients) (Fig. S1 in the Supplementary Ap-
pendix). The diagnosis of mantle-cell lymphoma 
was confirmed by central pathological review in 
471 patients (97% concordance). Demographic 
and disease characteristics were generally well 
balanced in the two groups (Table 1, and Table 
S3 in the Supplementary Appendix). Between-
group distributions according to baseline Ki-67 
expression and MIPIb risk category were similar 
(Table S4 in the Supplementary Appendix).
Overall, 406 patients (83%) in the two study 






All Patients  
(N = 487)
Age
Median (range) — yr 66 (34–82) 65 (26–88) 66 (26–88)
≥60 yr — no. (%) 177 (73) 178 (73) 355 (73)
Male sex — no. (%) 182 (75) 178 (73) 360 (74)
Race — no. (%)†
White 172 (70) 151 (62) 323 (66)
Asian  68 (28)  88 (36) 156 (32)
Other  4 (2)  4 (2)  8 (2)
MIPI risk category — no. (%)
Low  70 (29)  76 (31) 146 (30)
Intermediate  93 (38)  96 (40) 189 (39)
High  80 (33)  71 (29) 151 (31)
Missing data   1 (<1) 0   1 (<1)
Disease stage at diagnosis — no. (%)
II 16 (7) 12 (5) 28 (6)
III  42 (17)  49 (20)  91 (19)
IV 186 (76) 182 (75) 368 (76)
Elevated lactate dehydrogenase — no. (%)  86 (35)  88 (36) 174 (36)
Bone marrow involvement — no. (%) 171 (70) 165 (68) 336 (69)
Extranodal involvement — no. (%)‡ 137 (56) 139 (57) 276 (57)
Histologic subtype — no./total no. (%)
Blastoid 28/239 (12)  25/236 (11)  53/475 (11)
Nodular 97/239 (41) 109/236 (46) 206/475 (43)
Reason for ineligibility for stem-cell transplantation — no. (%)‡§
Age ≥60 yr or medically ineligible 202 (83) 205 (84) 407 (84)
Age <60 yr and not considered for transplantation  42 (17)  38 (16)  80 (16)
* There were no significant differences between the groups in the listed categories, except for race (P = 0.03). Percentages 
may not total 100 because of rounding. MIPI denotes mantle-cell lymphoma–specific International Prognostic Index; 
R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; and VR-CAP bortezomib, rituximab, cy-
clophosphamide, doxorubicin, and prednisone.
† Race was determined by investigators.
‡ The assessment was performed by the sponsor’s medical monitor.
§  Most patients were enrolled on the basis of ineligibility for transplantation owing to medical reasons (age, ≥60 years; or 
the presence of coexisting medical conditions, in accordance with current protocols).21 Patients were not considered for 
transplantation because of socioeconomic reasons (financial affordability), their decision not to undergo the procedure, 
or lack of transplant availability.
The New England Journal of Medicine 
Downloaded from nejm.org on March 9, 2021. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 372;10 nejm.org march 5, 2015948
groups (203 per group) received six or more cy-
cles of a study drug (median, 6 [range, 1 to 8] in 
the two groups). Treatment exposure was simi-
lar in the two groups, and most patients received 
the planned doses of each drug (Table S5 in the 
Supplementary Appendix). The mean relative dose 
intensity for drugs common to both regimens 
was 93% or higher. The mean relative dose in-
tensity was 80% for vincristine in the R-CHOP 
group (owing to the dose capping at 2 mg) and 
82% for bortezomib in the VR-CAP group.
Primary End Point
After a median follow-up of 40 months (40.3 
months in the R-CHOP group and 39.4 months in 
the VR-CAP group), 298 patients (61%) had dis-
ease progression or died, according to the inde-
pendent review committee. The median progres-
sion-free survival was 14.4 months in the R-CHOP 
group and 24.7 months in the VR-CAP group 
(hazard ratio favoring the VR-CAP group, 0.63; 
P<0.001) (Fig. 1). This result represented a rela-
tive improvement of 59% in the VR-CAP group, 
which exceeded the hypothesized 40% improve-
ment. According to the investigator assessment, 
307 patients (63%) had disease progression or 
died, and the median progression-free survival 
was 16.1 months in the R-CHOP group and 30.7 
months in the VR-CAP group (hazard ratio, 0.51; 
P<0.001), representing a 96% improvement (Fig. 
S2 in the Supplementary Appendix).
Preplanned sensitivity analyses showed that 
the difference between the assessments of the 
independent review committee and the investi-
gators was predominantly driven by the conser-
vative assessments of the independent review 
committee of progression with respect to tran-
sient fluid collections or transient lesions in pa-
tients who had a subsequent response or stable 
disease (Table S6 in the Supplementary Appen-
dix). There was a consistent improvement in the 
VR-CAP group with respect to progression-free 
survival on the basis of baseline characteristics 
across all prespecified subgroups (Fig. S3 in the 
Supplementary Appendix). Furthermore, VR-CAP 
had a consistent, significant effect on progres-
sion-free survival in both Ki-67–positive patients 
and in those with either no or low Ki-67 expres-
sion and across all MIPIb risk categories (Table 
S7 in the Supplementary Appendix).
Response Rate
Most patients had a tumor response according to 
the assessment of the independent review com-
mittee (Table 2). Rates of complete response were 
significantly lower in the R-CHOP group than in 
the VR-CAP group (42% vs. 53%). According to 
the independent assessment, in the R-CHOP 
group, as compared with the VR-CAP group, the 
median time to response was 1.6 months versus 
1.4 months, the median duration of overall re-
sponse was 15.1 months versus 36.5 months, and 
the median duration of complete response was 
18.0 months versus 42.1 months. Improvements 
in response rates and durability of response in the 
VR-CAP group, as compared with the R-CHOP 
group, were also observed for investigator- 
assessed responses (Table S8 in the Supplemen-
tary Appendix).
Other Secondary End Points
For R-CHOP versus VR-CAP, the median time to 
progression by independent assessment was 16.1 
months versus 30.5 months (hazard ratio, 0.58), 
the median time to the next antilymphoma ther-
apy was 24.8 months versus 44.5 months (hazard 
ratio, 0.50), and the median treatment-free inter-
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Figure 1. Kaplan–Meier Analysis of Progression-free Survival According to 
Independent Review (Intention-to-Treat Population).
The dashed lines indicate median values in the two study groups. R-CHOP 
denotes rituximab, cyclophosphamide, doxorubicin, vincristine, and predni-
sone, and VR-CAP bortezomib, rituximab, cyclophosphamide, doxorubicin, 
and prednisone.
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ratio, 0.50) (Table 2). At the final analysis, 132 pa-
tients (54%) in the R-CHOP group and 82 patients 
(34%) in the VR-CAP group had received subse-
quent antilymphoma therapy (Table S9 in the 
Supplementary Appendix); of these patients, 67 
(51%) and 32 (39%), respectively, had received 
two or more lines of therapy. The type of subse-
quent therapy was generally similar in the two 
groups, with 25 patients (19%) in the R-CHOP 
group and 3 (4%) in the VR-CAP group receiving 
subsequent bortezomib.
After the deaths of 158 patients (32%), overall 
Table 2. Secondary Efficacy End Points.*
End Point R-CHOP VR-CAP
Hazard Ratio or Risk Ratio  
(95% CI)†
Best response rate on independent review
No. of patients evaluated 228 229
Overall response — no. (%)‡ 204 (89) 211 (92) 1.03 (0.97–1.09)
Complete response — no. (%)§  95 (42) 122 (53)  1.29 (1.07–1.57)¶
Time to response on independent review
No. of patients evaluated 228 229
Median — mo 1.6 1.4  1.54 (1.26–1.89)‖
Duration of response on independent review
Overall response
No. of patients evaluated 204 211
Median — mo (95% CI) 15.1 (12.5–17.0) 36.5 (26.7–46.7) NA
Complete response
No. of patients evaluated 95 122
Median — mo (95% CI) 18.0 (14.0–23.4) 42.1 (30.7–49.1) NA
Time to progression
No. of patients evaluated 244 243
Median on independent review — mo 16.1 30.5  0.58 (0.45–0.74)‖
Median on investigator review — mo 16.8 35.0  0.47 (0.36–0.60)‖
Time to next antilymphoma treatment
No. of patients evaluated 244 243
Median — mo 24.8 44.5  0.50 (0.38–0.65)‖
Treatment-free interval
No. of patients evaluated 242 240
Median — mo 20.5 40.6  0.50 (0.38–0.65)‖
Overall survival
No. of patients evaluated 244 243
Median — mo 56.3 NR 0.80 (0.59–1.10)
Survival rate at 4 yr — % (95% CI) 54 (45–62) 64 (56–71) NA
* CI denotes confidence interval, NA not applicable, and NR not reached.
† Hazard ratios were calculated for time-to-event outcomes and risk ratios for response rates.
‡ Included in the category of overall response were patients who had a complete response or an unconfirmed complete 
response plus a partial response, regardless of verification by means of bone marrow assessment or measurement of 
the lactate dehydrogenase level.
§  Included in the category of complete response were patients who had a radiologic complete response or radiologic un-
confirmed complete response, which both had to be verified by evidence of bone marrow clearance and normalization 
of the lactate dehydrogenase level.
¶ P = 0.007.
‖ P<0.001.
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survival data were not mature at the time of this 
report. The median overall survival was 56.3 
months in the R-CHOP group and had not been 
reached in the VR-CAP group (hazard ratio, 0.80; 
P = 0.17) (Fig. 2). There was a between-group dif-
ference in 4-year survival of 10 percentage points 
(54% in the R-CHOP group vs. 64% in the VR-
CAP group).
Safety
Rates of adverse events of any grade and discon-
tinuations due to adverse events were similar in 
the R-CHOP group and the VR-CAP group, includ-
ing rates of drug-related adverse events (93% vs. 
96%) and discontinuations (6% vs. 8%) (Table S10 
in the Supplementary Appendix). Patients in the 
R-CHOP group, as compared with the VR-CAP 
group, had lower rates of grade 3 or higher ad-
verse events (all events, 85% vs. 93%; drug-related 
events, 80% vs. 91%) and serious adverse events 
(all events, 30% vs. 38%; drug-related events, 
21% vs. 32%).
Hematologic toxic effects were the most 
common adverse events (Table 3). The lower rates 
of thrombocytopenia that were observed in the 
R-CHOP group, as compared with the VR-CAP 
group, were reflected in a lower rate of platelet 
transfusions (3% vs. 23%). In the VR-CAP group, 
48 of 54 patients (89%) received platelet transfu-
sions during days 10 to 14 of the treatment cycles. 
Ten of 13 patients (77%) in the VR-CAP group 
who had the worst platelet counts (<10,000 per 
cubic millimeter) received platelet transfusions 
(Table S11 in the Supplementary Appendix). 
Thrombocytopenia led to a delay in next-cycle 
administration in 2% of patients in the R-CHOP 
group and 5% of those in the VR-CAP group. 
Rates of bleeding events were similar in the two 
groups (any grade, 12 patients [5%] vs. 15 patients 
[6%]; grade ≥3, 3 patients [1.3%] vs. 4 patients 
[1.6%]). Rates of neutropenia and infections or 
infestations were lower in the R-CHOP group 
than in the VR-CAP group (Table 3), consistent 
with reduced use of colony-stimulating factors 
(61% vs. 78%) and systemic antibacterial agents 
(65% vs. 81%) (Table S11 in the Supplementary 
Appendix). Peripheral neuropathy rates were 29% 
in the R-CHOP group and 30% in the VR-CAP 
group (grade ≥3, 4% vs. 8%). Peripheral neuropa-
thy was reversible in the majority of patients, 
with a complete resolution rate of 75% in the 
R-CHOP group and 81% in the VR-CAP group, in 
a median of 5.5 months and 3.0 months, respec-
tively (Table S11 in the Supplementary Appendix).
Rates of individual serious adverse events were 
less than 5% in each group, except for lower rates 
in the R-CHOP group than in the VR-CAP group 
for febrile neutropenia (8% vs. 11%), neutrope-
nia (5% each), and pneumonia (3% vs. 8%). Fatal 
events during treatment occurred in 14 patients 
(6%) in the R-CHOP group and 11 patients (5%) 
in the VR-CAP group; of these deaths, 7 (3%) 
and 5 (2%), respectively, were due to drug-relat-
ed adverse events: infection (in 3 patients), car-
diac failure (in 2 patients), hypotension, diar-
rhea, and renal failure (in 1 patient), and tumor 
lysis syndrome (in 1 patient) in the R-CHOP 
group and infection (in 3 patients), cardiac fail-
ure (in 1 patient), and pulmonary embolism (in 
1 patient) in the VR-CAP group (Table S10 in the 
Supplementary Appendix).
Discussion
LYM-3002 was a randomized, phase 3 study in-
corporating bortezomib into frontline treatment 
in patients with newly diagnosed mantle-cell 
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Figure 2. Kaplan–Meier Analysis of Overall Survival (Intention-to-Treat 
 Population).
The dashed line indicates the median value in the R-CHOP group. NR denotes 
not reached.
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baseline characteristics that were generally con-
sistent with those reported in other large stud-
ies21-24 and with those in the broader population 
of patients with mantle-cell lymphoma.20
The study met its primary end point by show-
ing a 59% improvement in median progression-
free survival with VR-CAP versus R-CHOP (hazard 
ratio, 0.63; P<0.001). Consistently, investigator 
assessment of progression-free survival also fa-
vored VR-CAP, with 96% improvement (hazard 
ratio, 0.51; P<0.001). Progression-free survival 
for patients receiving R-CHOP was at the lower 
end of the range that has been reported previ-
ously,7,21-24 reflecting stringent and frequent CT 
tumor assessment (every 6 to 8 weeks).
Subgroup analyses of progression-free sur-
vival indicated the superiority of VR-CAP over 
R-CHOP regardless of baseline characteristics. 
Progression-free survival also appeared to be 
more favorable regardless of Ki-67 expression 
status (an established prognostic marker in 
mantle-cell lymphoma).15-18 The shorter median 
progression-free survival observed in Ki-67–pos-
itive patients, as compared with patients with no 
or low Ki-67 expression, in the two study groups 
is consistent with the established negative prog-
nostic cutoff value of Ki-67 expression of more 
than 10%.15 When progression-free survival was 
analyzed according to MIPIb risk category (a 
validated disease-specific prognostic index, which 
became available for prognostic stratification 
after commencement of LYM-3002),19,20 the effect 
of VR-CAP was most apparent in the low- and 
intermediate-risk categories.
Significant improvements in secondary effi-
cacy end points were shown for VR-CAP versus 
R-CHOP after a relatively short treatment dura-
tion (median, 4.0 months for VR-CAP), including 
higher rates of complete response, which were 
more durable in the VR-CAP group than in the 
R-CHOP group (median duration, 3.5 years vs. 
1.5 years). There was a doubling of time to disease 
progression and time to the next antilymphoma 
treatment among patients receiving VR-CAP, as 
compared with those receiving R-CHOP. Patients 
in the VR-CAP group also benefited from an 
additional median period of 1.7 years without 
treatment. Although no significant difference in 
median overall survival was observed at the time 
of this report, a trend toward improved survival 
in the VR-CAP group (hazard ratio, 0.80; P = 0.17) 
plus a difference in 4-year survival of 10 percent-
age points were noted, even though only 32% of 
patients had died. Longer follow-up will be re-
quired to show whether the Kaplan–Meier curves 
will continue to separate. Subsequent therapies 
Table 3. Most Common Adverse Events (Safety Population).*
Adverse Event R-CHOP (N = 242) VR-CAP (N = 240)
Any Grade Grade ≥3 Any Grade Grade ≥3
no. of patients (%)
Any event 238 (98) 206 (85) 238 (99) 223 (93)
Hematologic event
Neutropenia 178 (74) 162 (67) 211 (88) 203 (85)
Thrombocytopenia  46 (19) 14 (6) 173 (72) 136 (57)
Anemia  90 (37)  33 (14) 122 (51)  37 (15)
Leukopenia  93 (38)  71 (29) 120 (50) 105 (44)
Lymphocytopenia  32 (13) 21 (9)  74 (31)  67 (28)
Febrile neutropenia  34 (14)  33 (14)  41 (17)  36 (15)
Gastrointestinal event
Diarrhea 22 (9)  5 (2)  73 (30) 12 (5)
Constipation  38 (16)  2 (1)  60 (25)   1 (<1)
Nausea  33 (14) 0  59 (25)   1 (<1)
Infection or infestation
Any 112 (46)  33 (14) 143 (60)  51 (21)





 69 (29) 10 (4)  73 (30) 18 (8)
Peripheral sensory 
neuropathy
 48 (20)  6 (2)  54 (22) 12 (5)
Other condition
Pyrexia  37 (15)  5 (2)  70 (29)  8 (3)
Fatigue  47 (19)  6 (2)  56 (23) 15 (6)
Cough 20 (8) 0  49 (20)  3 (1)
Decreased appetite  23 (10)  2 (1)  46 (19)  2 (1)
Asthenia  26 (11)  2 (1)  38 (16)  7 (3)
Peripheral edema  25 (10)   1 (<1)  37 (15)   1 (<1)
* The safety population included all the patients who underwent randomization 
and who received at least one dose of a study drug. Listed are adverse events 
of any grade that were reported in at least 15% of the patients and events of 
grade 3 or higher that were reported in at least 5% of the patients in either 
study group during the treatment period. Incidence is based on the number 
of patients with at least one adverse event. In addition to the listed events, 
 alopecia, insomnia, neuralgia, stomatitis, and vomiting of any grade were re-
ported in at least 10% but less than 15% of the patients in the VR-CAP group.
† This category includes the following preferred terms: peripheral sensory neu-
ropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral 
sensorimotor neuropathy.
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were generally similar for patients with disease 
progression in the two study groups.
A limitation of our study is that rituximab 
maintenance therapy was not used; current rec-
ommendations4,6 were not established when the 
study began. The use of VR-CAP with rituximab 
maintenance therapy could further prolong pro-
gression-free survival and potentially extend 
overall survival.
The improved efficacy of VR-CAP over R-CHOP 
was accompanied by additional toxic effects. 
However, there was no significant effect on the 
number of completed cycles, median dose inten-
sity for drugs common to both regimens, or rates 
of discontinuations or deaths related to adverse 
events. The VR-CAP safety profile was expected 
on the basis of previous experience with bort-
ezomib plus R-CHOP in non-Hodgkin’s lym-
phomas25-27 and with single-agent bortezomib 
in relapsed or refractory mantle-cell lympho-
ma.9-11,28 Previous experience from a noncom-
parative phase 2 study of weekly or twice-weekly 
bortezomib plus R-CHOP suggested that week-
ly administration of bortezomib may be asso-
ciated with reduced rates of some grade 3 or 4 
hematologic and nonhematologic toxic effects 
but also with a reduced rate of complete re-
sponse.25
Rates of peripheral neuropathy, a known 
toxicity associated with bortezomib and vin-
cristine,8-11,22,24,28,29 were similar in the two 
groups, and events appeared to resolve more 
quickly in the VR-CAP group. Peripheral neuropa-
thy rates also compared favorably with those 
reported in trials involving patients with mul-
tiple myeloma (ranging from 37% to 44%).30 
Bortezomib was administered intravenously in 
our study, but subcutaneous administration 
may offer improved safety, including a reduced 
risk of peripheral neuropathy,31 with added pa-
tient convenience.32
Rates of thrombocytopenia were increased in 
the VR-CAP group, but there was no between-
group difference in rates of clinically significant 
bleeding events, similarly low rates of cycle de-
lays due to thrombocytopenia, and no trend 
toward cumulative toxicity on thrombopoiesis, 
reflecting the previously reported transient, 
cyclical nature of platelet-count reduction with 
bortezomib.33-36 Notably, supportive therapies, 
which were allowed according to the protocol, 
were a key aspect of patient treatment in this 
study. The higher rate of platelet transfusion in 
the VR-CAP group may have been associated with 
the aim of maximizing bortezomib dose inten-
sity; data indicate that the primary use of plate-
let transfusion was prophylactic (as allowed ac-
cording to the protocol at the investigators’ 
discretion) to avoid withholding the bortezomib 
dose on day 11 because of a platelet count of less 
than 25,000 per cubic millimeter, rather than 
therapeutic, because of a platelet count of less 
than 10,000 per cubic millimeter.
In conclusion, a significant prolongation of 
progression-free survival and improvements in 
secondary efficacy end points were observed 
with VR-CAP as compared with R-CHOP. This 
improvement was accompanied by additional, 
predominantly hematologic toxicity.
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